SCHEMBL628786

SCHEMBL628786

CN1c2ccccc2Sc2cc(O)ccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.68
NOX1 Q9Y5S8 9/20 0.65
L3MBTL1 Q9Y468 2/20 0.65
MEN1 O00255 1/20 0.65
ADRA2A P08913 1/20 0.65
ADRA2B P18089 1/20 0.65
ADRA2C P18825 1/20 0.65
CHRM3 P20309 1/20 0.65
SLC6A2 P23975 1/20 0.65
HTR2C P28335 1/20 0.65
SLC6A4 P31645 1/20 0.65
DRD3 P35462 1/20 0.65
HTR2B P41595 1/20 0.65
KMT2A Q03164 1/20 0.65
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231247 0.82 MAOA (1.00) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL29377505 0.82 MAOA (1.00) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL7170967 0.81 MAOA (0.73) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL628765 0.80 MAOA (0.70) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL628732 0.79 NOX1 (1.00) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL628020 0.79 MAOA (0.68) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL19071672 0.79 MAOA (0.68) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL629053 0.79 MAOA (0.68) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL19071782 0.79 MAOA (0.68) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL7125071 0.78 MAOA (0.61) MAOANOX1L3MBTL1MEN1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1883987-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M Innovative Properties Company (US) 2008-02-06 EP claimed
WO-2006124738-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-23 WO claimed
US-20060263697-A1 Substituted phenothiazine redox shuttles for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY 2006-11-23 US claimed
EP-1883987-B1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES CO (US) 2012-02-22 EP disclosed
US-7615312-B2 Electrolytic cells; phenothiazine compound has oxidation potential above positive electrode recharged potential and serves as cyclable redox chemical shuttle providing cell overcharge protection 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-11-10 US disclosed
EP-1883987-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M Innovative Properties Company (US) 2008-02-06 EP disclosed
WO-2006124738-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-23 WO disclosed
US-20060263697-A1 Substituted phenothiazine redox shuttles for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY 2006-11-23 US disclosed
EP-0663393-B1 3-Amino/hydroxy-4- 4-benzoylphenylcarboxylamino/oxy -azepanes and their homologies as protein kinase inhibitors HOFFMANN LA ROCHE (CH) 2000-07-05 EP disclosed
US-5914406-A ENZYME INHIBITOR; USEFUL FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMAN-LA ROCHE INC. (US) 1999-06-22 US disclosed
US-5830902-A SQUALENE SYNTHASE INHIBITOR YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-11-03 US disclosed
US-5750706-A TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMANN-LA ROCHE INC. (US) 1998-05-12 US disclosed
EP-0812840-A1 NOVEL QUINUCLIDINE DERIVATIVES HAVING TRICYCLIC FUSED HETERO RING YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1997-12-17 EP disclosed
US-5583222-A ANTIINFLAMMATORY AGENTS FOR TREATMENT OF SKIN DISORDERS HOFFMANN-LA ROCHE INC. (US) 1996-12-10 US disclosed
EP-0663393-A1 Novel 3-amino/hydroxy-4- 4-benzoylphenylcarboxylamino/oxy -azepanes and their homologies as protein kinase inhibitors F. HOFFMANN-LA ROCHE AG (CH) 1995-07-19 EP disclosed